Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)

Lymphoma Clinical Trial

Official title:

A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01004718
• Other study ID #: UPCC 21408
• Secondary ID: NCI-2009-01348
• Status: Completed
• Phase: N/A
• Start date: May 2009
• Est. completion date: November 5, 2014

Study information

• Verified date: April 2021
• Source: Abramson Cancer Center of the University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell lymphoma.

Description:

OBJECTIVES:

I. Assess the feasibility of detection and quantification of differences in the temporal and spatial distribution of FDG uptake between lesions of HL and DLBCL.

OUTLINE:

Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans 60 and 180 minutes after FDG administration.

After completion of study, patients are followed for 24 hours.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: November 5, 2014
• Est. primary completion date: July 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with measurable disease by any imaging technique or physical examination.

Exclusion Criteria:

• Pregnant or nursing,

• Uncontrolled diabetes mellitus,

• Active infection,

• Inability to give informed consent or to comply with all study procedures,

• Subjects may be excluded at the discretion of the principal investigator or study team members.

Related Conditions & MeSH terms

• Hodgkin Disease
• Lymphoma
• Lymphoma, Large B-Cell, Diffuse

Intervention

Radiation:
• Fludeoxyglucose F18
Undergo FDG PET/CT scans

Procedure:
• Computed Tomography
Undergo FDG PET/CT scans
• Positron emission tomography
Undergo FDG PET/CT scans

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center of the University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage Change in Maximum Lesional FDG Uptake From 60 to 180 Minutes After FDG Administration	Lesional fluorodeoxyglucose (FDG) uptake is measured by standardized uptake value (SUV). The study compared the percentage of change in maximum SUV over 2 hours (first measure was 60 minutes post-administration and second timepoint was 180 minutes post-administration).	2 hours (between 60 minutes post-administration and 180 minutes post-administration)